Current Report · Items 7.01, 8.01, 9.01 · 8-K

Neuropace, Inc.

NPCENASDAQEQUITYCurrent

Regulation FD Disclosure · Other Events

Filed May 27, 2025Accepted May 27, 2025, 8:09 AM EDTCIK 1528287Accession 0001193125-25-126268

Company context

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Current securities

NPCENASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 27, 2025, NeuroPace, Inc. (the “Company) issued a press release announcing, among other matters, the reaffirming of guidance for fiscal year 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and in the section of Exhibit 99.1 hereto entitled “Full-Year 2025 Financial Guidance” is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. On May 27, 2025, the Company issued a press release announcing, among other things, topline results from first-year data in the NAUTILUS study. A copy of the press release is attached hereto as Exhibit 99.1, and the section of Exhibit 99.1 hereto entitled “NAUTILUS Study Results” is hereby incorporated herein by reference.

Filed exhibits (1)

EX-99.1 (by filename) d909963dex991.htm

EX-99.1 2 d909963dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study - NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy - Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS ® System - Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants - Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing more favorable rates of median seizure reduction than observed in the Company’s randomized controlled trial supporting its current indication in focal epilepsy Mountain View, Calif. - May 27, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the preliminary primar…

Open exhibit ↗

Get the free weekly BCS email.